Stock Events

Stock Events

Oncoinvent ASA. 

SEK407.13
72
-SEK0.00-0% Thursday 08:00

Statistics

Day High
-
Day Low
-
52W High
407.13
52W Low
4.07
Volume
-
Avg. Volume
0
Mkt Cap
15.91B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

27AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q2 2026
-1.39
-1.15
-0.9
-0.65
Expected EPS
N/A
Actual EPS
N/A

Financials

-16,625.97%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.65MRevenue
-274.58MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BGBIOO.ST. It's not an investment recommendation.
MPC Container Ships ASA
2
MPCC.OL
Aker BP ASA
2
AKRBP.OL
Salmon Evolution ASA
2
SALME.OL
SED Energy
2
ENH.OL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics, including those in oncology, which competes with BerGenBio's cancer-focused pipeline.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. is a biotechnology company that develops and produces medicines in areas including oncology/hematology, competing directly with BerGenBio's cancer treatment developments.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is involved in the research, development, and commercialization of drugs in areas such as oncology, directly competing with BerGenBio's therapeutic areas.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that produces pharmaceuticals across various areas, including cancer, making it a competitor to BerGenBio.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb Company offers biopharmaceutical products, including those for cancer treatment, competing with BerGenBio's oncology focus.
Novartis
NVS
Mkt Cap292.35B
Novartis AG engages in the research, development, manufacturing, and marketing of healthcare products, including oncology, which competes with BerGenBio's product range.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is a research-based global biopharmaceutical company with a broad range of products including oncology treatments, competing with BerGenBio.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG focuses on pharmaceuticals and diagnostics in oncology, among other areas, directly competing with BerGenBio's cancer therapies.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with BerGenBio.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is engaged in the discovery, development, manufacture, and sale of a range of pharmaceutical products, including those for cancer, making it a competitor to BerGenBio.

About

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. The company's Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase I clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is headquartered in Bergen, Norway.
Show more...
CEO
Oystein Soug
Employees
13
Country
Other
ISIN
NO0013711713
WKN
000A41YN5

Listings

ST
SE
BGBIOO.ST
STU
DE
7BG.STU
MU
DE
7BG.MU
LSE
GB
0RU5.LSE

0 Comments

Share your thoughts

FAQ

What is Oncoinvent ASA. stock price today?▼
The current price of BGBIOO.ST is SEK407.13 SEK — it has decreased by -0% in the past 24 hours. Watch Oncoinvent ASA. stock price performance more closely on the chart.
What is Oncoinvent ASA. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Oncoinvent ASA. stocks are traded under the ticker BGBIOO.ST.
Is Oncoinvent ASA. stock price growing?▼
BGBIOO.ST stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Oncoinvent ASA. has showed a +3,971.67% increase.
What is Oncoinvent ASA. market cap?▼
Today Oncoinvent ASA. has the market capitalization of 15.91B
What is Oncoinvent ASA. revenue for the last year?▼
Oncoinvent ASA. revenue for the last year amounts to 1.65M SEK.
What is Oncoinvent ASA. net income for the last year?▼
BGBIOO.ST net income for the last year is -274.58M SEK.
How many employees does Oncoinvent ASA. have?▼
As of September 07, 2026, the company has 13 employees.
In which sector is Oncoinvent ASA. located?▼
Oncoinvent ASA. operates in the Health & Wellness sector.
When did Oncoinvent ASA. complete a stock split?▼
The last stock split for Oncoinvent ASA. was on January 20, 2026 with a ratio of 1:100.
Where is Oncoinvent ASA. headquartered?▼
Oncoinvent ASA. is headquartered in Bergen, Other.